Magnus Essand

5.7k total citations
124 papers, 4.1k citations indexed

About

Magnus Essand is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Magnus Essand has authored 124 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 50 papers in Oncology and 49 papers in Genetics. Recurrent topics in Magnus Essand's work include Virus-based gene therapy research (48 papers), CAR-T cell therapy research (40 papers) and Immunotherapy and Immune Responses (33 papers). Magnus Essand is often cited by papers focused on Virus-based gene therapy research (48 papers), CAR-T cell therapy research (40 papers) and Immunotherapy and Immune Responses (33 papers). Magnus Essand collaborates with scholars based in Sweden, United States and United Kingdom. Magnus Essand's co-authors include Di Yu, Mohanraj Ramachandran, Angelica Loskog, Thomas H. Tötterman, Ira Pastan, Miika Martikainen, Byung Kook Lee, George Vasmatzis, Berith Nilsson and Anna Dimberg and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Magnus Essand

122 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Magnus Essand Sweden	34	1.9k	1.6k	1.4k	1.1k	351	124	4.1k
Angelica Loskog Sweden	37	2.8k 1.5×	1.3k 0.8×	2.2k 1.6×	1.2k 1.1×	420 1.2×	103	4.6k
Branden S. Moriarity United States	29	1.4k 0.8×	2.5k 1.6×	1.1k 0.8×	579 0.5×	204 0.6×	95	4.2k
Paolo Vezzoni Italy	40	1.6k 0.9×	3.6k 2.2×	1.9k 1.4×	1.4k 1.2×	149 0.4×	175	6.7k
Masatoshi Tagawa Japan	35	1.7k 0.9×	2.3k 1.4×	1.5k 1.1×	1.0k 0.9×	123 0.4×	210	4.6k
Scott J. Diede United States	24	2.5k 1.4×	1.9k 1.2×	1.3k 0.9×	710 0.6×	105 0.3×	67	4.3k
Elizabeth L. Buza United States	27	1.1k 0.6×	1.4k 0.9×	523 0.4×	905 0.8×	164 0.5×	48	2.9k
Brad St. Croix United States	32	1.8k 1.0×	4.1k 2.5×	761 0.5×	444 0.4×	295 0.8×	58	6.0k
Monica Fedele Italy	46	1.2k 0.7×	4.5k 2.8×	588 0.4×	572 0.5×	205 0.6×	129	6.5k
Pierre Cordelier France	36	1.9k 1.0×	2.5k 1.5×	386 0.3×	451 0.4×	189 0.5×	104	4.5k
Candelaria Gomez‐Manzano United States	41	3.1k 1.7×	3.7k 2.3×	769 0.6×	2.6k 2.3×	254 0.7×	141	6.1k

Countries citing papers authored by Magnus Essand

Since Specialization

Citations

This map shows the geographic impact of Magnus Essand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magnus Essand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magnus Essand more than expected).

Fields of papers citing papers by Magnus Essand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magnus Essand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magnus Essand. The network helps show where Magnus Essand may publish in the future.

Co-authorship network of co-authors of Magnus Essand

This figure shows the co-authorship network connecting the top 25 collaborators of Magnus Essand. A scholar is included among the top collaborators of Magnus Essand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magnus Essand. Magnus Essand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Essand, Magnus, et al.. (2025). Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains. Science Immunology. 10(103). eado2054–eado2054. 7 indexed citations

Dimberg, Anna, et al.. (2025). News from the T cell trogocytosis front. Trends in Immunology. 46(10). 677–689.

Aramesh, Morteza, Di Yu, Magnus Essand, & Cecilia Persson. (2024). Enhanced Cellular Uptake through Nanotopography‐Induced Macropinocytosis. Advanced Functional Materials. 34(28). 3 indexed citations

Martikainen, Miika, Roberta Lugano, Ilkka Pietilä, et al.. (2024). VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier. Nature Communications. 15(1). 10718–10718. 5 indexed citations

Ramachandran, Mohanraj, Tanja Lövgren, Claudio Mirabello, et al.. (2023). Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients. Clinical Cancer Research. 29(20). 4139–4152. 8 indexed citations

Lövgren, Tanja, Angelica Loskog, Magnus Essand, et al.. (2022). Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy. Cancer Imaging. 22(1). 76–76. 11 indexed citations

Fayad, Sarah M., Daniel Y. Kim, Karl Petri, et al.. (2022). CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation. Molecular Therapy — Nucleic Acids. 28. 450–461. 28 indexed citations

Martikainen, Miika, Mohanraj Ramachandran, Roberta Lugano, et al.. (2021). IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma. Molecular Therapy — Oncolytics. 21. 37–46. 18 indexed citations

Hooren, Luuk van, Alessandra Vaccaro, Mohanraj Ramachandran, et al.. (2021). Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nature Communications. 12(1). 4127–4127. 107 indexed citations

10.

Pietilä, Ilkka, Hiroshi Kaito, Elisabet O. Sjöström, et al.. (2018). Leukocyte Differentiation by Histidine-Rich Glycoprotein/Stanniocalcin-2 Complex Regulates Murine Glioma Growth through Modulation of Antitumor Immunity. Molecular Cancer Therapeutics. 17(9). 1961–1972. 18 indexed citations

11.

Enblad, Gunilla, Hannah Karlsson, Jessica Wenthe, et al.. (2018). A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clinical Cancer Research. 24(24). 6185–6194. 207 indexed citations

12.

Xie, Yuan, Anders Sundström, E‐Jean Tan, et al.. (2018). LGR5 promotes tumorigenicity and invasion of glioblastoma stem‐like cells and is a potential therapeutic target for a subset of glioblastoma patients. The Journal of Pathology. 247(2). 228–240. 21 indexed citations

13.

Essand, Magnus, et al.. (2017). CAR T-Cells with Induced Secretion of Helicobacter Pylori Neutrophil-Activating Protein (HP-NAP) Yields Improved Anti-Tumor Activity and Reduced Immunosuppression. Molecular Therapy. 25. 288–288. 1 indexed citations

14.

Ramachandran, Mohanraj, Di Yu, Matheus Dyczynski, et al.. (2016). Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus. Clinical Cancer Research. 23(6). 1519–1530. 44 indexed citations

15.

Kundu, Soumi, Anqi Xiong, Grzegorz Wicher, et al.. (2016). Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival. Molecular Cancer Research. 14(12). 1243–1253. 52 indexed citations

16.

Langenkamp, Elise, Lei Zhang, Roberta Lugano, et al.. (2015). Elevated Expression of the C-Type Lectin CD93 in the Glioblastoma Vasculature Regulates Cytoskeletal Rearrangements That Enhance Vessel Function and Reduce Host Survival. Cancer Research. 75(21). 4504–4516. 59 indexed citations

17.

Jin, Chuan, et al.. (2013). Tat-PTD-Modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy. Human Gene Therapy. 24(8). 766–775. 8 indexed citations

18.

Muthana, Munitta, Yung‐Yi Chen, Abigail Welford, et al.. (2012). Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation. Cancer Research. 73(2). 490–495. 86 indexed citations

19.

Muthana, Munitta, Athina Giannoudis, Simon D. Scott, et al.. (2011). Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. Cancer Research. 71(5). 1805–1815. 101 indexed citations

20.

Nilsson, Sten, et al.. (1997). E4, A New Monoclonal Antibody Identifying a Human Prostatic Cell Surface Antigen. Cancer Biotherapy and Radiopharmaceuticals. 12(6). 395–403. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact